Fig 2: Expression of ANG2 in human gastric cancer tissues. (A) IHC staining of ANG2 and Pan CK in matched normal gastric tissue and primary GC (n = 12). (B) Expression of ANG2 and Pan CK in GC omental metastatic tissues (n = 12); arrowhead, ANG2-positive cells. Representative images are shown (magnification, 200×; scale bar represents 0.05 µm). IHC quantification is shown on the right. *** p < 0.001.

Fig 3: NDPK-B depletion upregulates Ang2 and Tie2 in endothelial cells. (A) HUVECs were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +). (A) Representative immunoblots of Tie2, Ang2, NDPK-B, and ?-Tubulin in NDPK-B depleted HUVECs treated for 24 h without (-) or with HG, (+). Quantification of Ang2 (B) and Tie2 (C) levels, (n = 4). (D) Tie2 mRNA expression normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA (n = 4). HMECs and HRMVECs were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +). (E) Representative immunoblots of Tie2, Ang2, NDPK-B, and ?-Tubulin in HMECs. Quantification of Ang2 (F) and Tie2 (G) levels, (n = 3). (H) Representative immunoblots of Tie2, Ang2, NDPK-B, and ?-Tubulin in HRMVECs. (I,J) Quantification of Ang2 (I) and Tie2 (J) levels, (n = 5). All protein contents were normalized to ?-Tubulin. * p < 0.05.

Fig 4: Anti-angiogenic therapies induce the expression of CXCR4 and SDF1a in experimental glioblastomas (1). a Graphical distribution of tumor weights at the end of treatment cycle of 35 days (mean ± standard deviation, (SD)). Each column included ten tumors. b Size-based grouping of representative U87-derived tumors from animals of control (three tumors) or treated (three tumors) with sunitinib or bevacizumab. c Western blot evaluation of single three tissue extracts from smaller and larger tumors in each group of treatment. Each lane was loaded with 100 µg of protein. CXCR4, TGFßRI, Ang2, and Ang1 expression was normalized versus actin. d Statistical analyses of correlation performed among the levels of CXCR4 (adjusted densitometric units by western blots normalized versus actin) and tumor weight for all 30 tissues (ten tissue extracts for three treatments). e Statistical analyses of correlation performed on untreated tumors (ten tissue extracts). f Statistical analyses of correlation performed on bevacizumab treated tumors (ten tissue extracts). g Statistical analyses of correlation performed on sunitinib treated tumors (ten tissue extracts). h, i Histological appearance (h) and CXCR4 and Tie2 expression (i) in untreated and treated with bevacizumab or sunitinib U87 xenografts with resolution of ×100, ×200, and ×400

Fig 5: Ang2 plasma levels in perioperative NSCLC patients. Values are expressed as mean ± SD. *** P < 0.001, ** P = 0.003 (POD42) or 0.004 (POD56), compared to corresponding POD-1; ^^^P < 0.001, ^^P = 0.008, ^P = 0.02 (POD-1 (1, 3)), 0.03 (POD-1 (14)), 0.02 (POD-1 (42)), 0.04 (POD-1 (56)), compared to control. Ang2 = angiopoietin-2, NSCLC = nonsmall cell lung cancer, POD = postoperative day, POD-1 (1, 3) = preoperative control for POD1 and POD3 samples, POD-1 (14) = preoperative control for POD14 sample, POD-1 (28) = preoperative control for POD28 sample, POD-1 (42) = preoperative control for POD42 sample, POD-1 (56) = preoperative control for POD56 sample, SD = standard deviation.